Iconovo AB (publ) (STO:ICO)
Sweden · Delayed Price · Currency is SEK | Market Cap | 109.16M +278.2% |
| Revenue (ttm) | 13.83M -38.9% |
| Net Income | -40.29M |
| EPS | -0.77 |
| Shares Out | 96.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,054 |
| Average Volume | 79,454 |
| Open | 1.100 |
| Previous Close | 1.135 |
| Day's Range | 1.100 - 1.155 |
| 52-Week Range | 0.906 - 2.790 |
| Beta | 0.38 |
| RSI | 43.42 |
| Earnings Date | Aug 20, 2026 |
About Iconovo AB
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for ... [Read more]
Financial Performance
In 2025, Iconovo AB's revenue was 14.53 million, a decrease of -39.46% compared to the previous year's 24.00 million. Losses were -43.36 million, 5.41% more than in 2024.
Financial StatementsNews
Iconovo AB Quarterly report: Q1 2026
Iconovo AB has published its Q1 2026 quarterly earnings report on April 24, 2026.
Iconovo AB Transcript: DNB Carnegie Healthcare Seminar 2026
Revised summary: The company is shifting from a tech platform to monetizing a diverse pipeline of inhaled medicines, including generics and biologics. Regulatory changes and a patent cliff offer market opportunities. Key projects are in licensing and preclinical stages, with partnerships and funding supporting full pharma operations and long-term value.
Iconovo AB Quarterly report: Q4 2025
Iconovo AB has published its Q4 2025 quarterly earnings report on February 13, 2026.
Iconovo AB Annual report: Q4 2025
Iconovo AB has published its Q4 2025 annual report on February 13, 2026.
Iconovo AB Earnings Call Transcript: Q3 2025
Major cost reductions and a shift to a commercial focus defined the quarter, with progress on key projects including EcoPre, EcoRes, and intranasal semaglutide. Regulatory changes have improved prospects for generics, and new board members are driving unified strategic direction.
Iconovo AB Quarterly report: Q3 2025
Iconovo AB has published its Q3 2025 quarterly earnings report on October 27, 2025.
Iconovo AB Quarterly report: Q2 2025
Iconovo AB has published its Q2 2025 quarterly earnings report on July 14, 2025.
Iconovo AB Transcript: Investor Update
A fully guaranteed SEK 36.6 million rights issue will fund commercialization of inhalation platforms, with a leaner organization and significant cost savings. Focus areas include SymbiCort and Ellipta generics, and intranasal semaglutide, targeting large global markets and aiming for key licensing deals in the next two years.